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Costs were calculated on the actual resources used by
each patient and assigned to the treatment group to which
the patient was randomized. Direct medical resource use
data was costed over six months post transplantation. A
local health economist collected cost information from
published sources and personal interviews with clinicians.
Costs were collected on study drug, concomitant med-
ication, hospitalization, dialysis, and rejection episodes.
To explore the impact of any variability of costs, a one-
way sensitivity analysis was conducted. RESULTS: Six
months after transplantation, patient survival was 99.3%
(Tac) and 98.5% (CyA), p = 0.366; graft survival was
94.6% (Tac) and 91.9% (CyA), p = 0.139. The incidence
of acute graft rejection was 32.5% (Tac) and 51.3%
(CyA), p < 0.0001. Cost-minimization analysis revealed
savings for tacrolimus (per patient) of Euro 583–1874 
for surviving patients, and Euro 781–2305 for patients
with functioning grafts. Tacrolimus was cost-effective for
patients with rejection-free grafts; savings per patient
were Euro 4627–9919. The tacrolimus group consistently
had lower total costs than the cyclosporin group. The cost
advantages for tacrolimus were a result of lower overall
hospitalization costs and lower incidences of dialysis 
and graft rejection. CONCLUSION: A sensitivity analy-
sis regarding the main cost drivers (hospitalization, study
drug, and concomitant medication) generally conﬁrmed
the robustness of this ﬁnding across all three countries.
PRK8
COSTS AND CLINICAL CONSEQUENCES OF
ALFUZOSIN AND DOXAZOZIN IN BENIGN
PROSTATIC HYPERPLASIA IN UKRAINE
Zaliska O, Zchuravchak A
Lviv Medical University, Lviv, Ukraine
OBJECTIVE: Randomized controlled clinical trials have
demonstrated, that alfuzosin (dalfaz R) is comparable to
doxazosin (cardura) in benign prostatic hyperplasia. We
compare the costs and clinical consequences of alfuzosin
vs doxazosin from the perspective of public health care
in Ukraine. Both drugs provide long-lasting relief of
symptoms. METHODS: We compared the rates of PSA
assay, of prostate volume, of while urinary ﬂow (Qmax).
Patients ﬁlled in both the generic IPSS. To calculate the
drug-acquisition costs. RESULTS: A total of 106 patients
(54 alfuzosin, 52 doxazosin) were treated in 6 months.
The mean age of patients was 63.7 years. Relief was seen
as early as one week after the initiation of therapy. We
compared the rates at 1, 3, and 6 months; the prostate
volume decreased by 18% and 19% in the doxazosin and
alfuzosin groups, respectively, while urinary ﬂow (Qmax)
increased by 28 to 29%. The mean percent change in IPSS
was 39.8% (p < 0.05). Overall symptoms improved in
two groups. The direct costs of alfuzosin were 910.0
UAH vs doxazosin 714.1 (1USD = 5.3 UAH) per one
patient. The total cost of 100 patients treated with dox-
azosin were decrease by 27.4% vs alfuzosin. CONCLU-
SIONS: There was no difference in the clinical
consequences of doxazosin vs alfuzosin treatment. Our
study showed that the treatment with doxazosin may
offer economic advantages over alfuzosin, the results 
may provide a basis for creation of formulary system in
Ukraine.
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OBJECTIVE: To evaluate the cost-effectiveness of 
tamsulosin, doxazosin or terazosin as initial treatments 
for moderate benign prostatic hyperplasia (BPH).
METHODS: A decision analytic model is used to project
the costs and effectiveness of treatment at 6-month inter-
vals over three years following initiation of therapy with
tamsulosin, doxazosin or terazosin. Patients initially
treated with doxazosin or terazosin who discontinue due
to hypotensive events are switched to tamsulosin. Finas-
teride is added in the event of treatment failure not related
to adverse events. Medical treatment failures transition 
to transurethral resection of the prostate (TURP) and, if
needed, a second TURP. Values for treatment failure rates
and clinical event cost parameters are derived from the
literature. Only direct medical costs are included and are
discounted by 3% per year. Effectiveness is measured as
successful medical treatment (without TURP) over three
years. RESULTS: In the reference case, discounted BPH-
related total direct medical costs over 3 years are $3715,
$3756, and $3992 for generic terazosin, generic doxa-
zosin, and tamsulosin, respectively. Estimated medical
treatment success rates at 3 years are 72.41% for tamsu-
losin, 69.62% for terazosin and 69.28% for doxazosin.
The incremental cost for tamsulosin vs. terazosin is $278,
which yields an incremental cost-effectiveness ratio of
$9964 per success. Decision model results are sensitive to
parameter values for treatment efﬁcacy, drug costs, dis-
continuation rates, and dosing frequency. CONCLU-
SION: As an initial medical therapy for moderate BPH,
tamsulosin is more effective than generic terazosin or
doxazosin, with an incremental cost of about $93 per
year or about $7.75 per month. From a payer’s perspec-
tive, with differential generic/brand patient co-pays of
$8/month or more, tamsulosin is cost saving.
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